January data updates expected
JPMorgan's Nov. 10 note pointed to expected January updates on two monotherapy programs. The bank anticipates initial data for brain-penetrant '456' across several indications, including non-small cell lung cancer and glioblastoma, as well as an update on vopimetostat, also called vopi, in lung cancer.
The bank also outlined its view of vopimetostat's potential in combination treatments. JPMorgan said Tango's work had opened a path for the drug to become a core treatment for pancreatic ductal adenocarcinoma. It also saw opportunities for the portfolio in other tumor types and the MTAP wildtype setting, Investing.com reported.
Shares and other analysts' targets
Tango shares were trading at $22.74 at the time of the Investing.com report, a gain of 157% year to date. The report described the analyst consensus as strongly favoring buying the stock, with price targets spanning $24 to $69.
Other recent analyst actions included a Stifel target increase from $40 to $55, supported by peak sales estimates of approximately $7.1 billion. Wedbush lifted its target to $45, while William Blair began coverage with an Outperform rating and a $42 target, according to Investing.com.
The report also cited Tango's second-quarter 2026 net loss of $0.37 per share, compared with the $0.30-per-share loss H.C. Wainwright had previously estimated.
